After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.

Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.

Individual and small group plans in the commercial insurance market are not seeing ‘a large enough change in clinical indications or practice patterns to warrant a change to the current mapping of GLP-1 drugs,’ final rule states.